AzurRx BioPharma, Inc. (AZRX) Stock Analysis

AzurRx BioPharma, Inc. (AZRX) Healthcare & Pipeline Overview

AzurRx BioPharma, Inc. is a clinical-stage biotechnology company specializing in the development of non-systemic biologics targeting gastrointestinal disorders, including exocrine pancreatic insufficiency and antibiotic-associated diarrhea. Their pipeline focuses on addressing unmet needs in GI health through innovative therapeutic proteins, positioning them in a competitive biotechnology landscape.

What Is the Investment Thesis for AZRX?

AzurRx BioPharma presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on non-systemic biologics for GI disorders addresses a significant market need. Successful clinical trials and regulatory approvals for MS1819 and AZX1101 could drive substantial value. Key value drivers include positive clinical data readouts, strategic partnerships, and potential acquisition by a larger pharmaceutical company. The company's small size and limited resources pose risks, including potential delays in clinical development and the need for additional financing. The P/E ratio of 0.20 indicates potential undervaluation, but this must be considered in the context of the company's developmental stage and inherent risks.

Based on FMP financials and quantitative analysis

AZRX Key Highlights

AzurRx BioPharma is focused on developing non-systemic biologics for gastrointestinal disorders, addressing a significant unmet medical need.

• The company's lead product candidate, MS1819, targets exocrine pancreatic insufficiency (EPI), a condition associated with chronic pancreatitis and cystic fibrosis.
• AZX1101, another key pipeline asset, is being developed for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
• The company's market capitalization is $3.43M, reflecting its early-stage development status.
• AzurRx BioPharma operates with a small team of 12 employees, indicating a lean operational structure.

Who Are AZRX's Competitors?

AZRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AZRX's Key Strengths?

Novel non-systemic biologics approach.

• Pipeline focused on unmet needs in GI disorders.
• Potential for targeted therapies with fewer side effects.
• Experienced management team.

What Are AZRX's Weaknesses?

Limited financial resources.

• Small team size.
• Dependence on successful clinical trials.
• High regulatory risk.

What Could Drive AZRX Stock Higher?

MS1819 Phase 3 clinical trial data readout for exocrine pancreatic insufficiency (EPI).

• AZX1101 clinical trial initiation for the prevention of hospital-acquired infections.
• Potential strategic partnerships with larger pharmaceutical companies.
• Regulatory discussions with the FDA regarding MS1819 and AZX1101 development pathways.

What Are the Key Risks for AZRX?

Financial-distress signal — its Altman Z-Score of -9.82 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-49.8%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Clinical trial failures for MS1819 or AZX1101.
• Regulatory delays or rejection of MS1819 or AZX1101.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on securing additional funding to support clinical development.
• Intellectual property challenges or patent infringement claims.

What Are the Growth Opportunities for AZRX?

• MS1819 Clinical Development: A significant growth opportunity lies in the successful clinical development and commercialization of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI). Positive Phase 3 trial results and subsequent regulatory approval could establish MS1819 as a leading therapy in this space, capturing a substantial market share within the next 3-5 years.
• AZX1101 for Infection Prevention: The development of AZX1101 for the prevention of hospital-acquired infections and antibiotic-associated diarrhea represents another key growth driver. With rising concerns about antibiotic resistance and the increasing incidence of nosocomial infections, AZX1101 has the potential to address a critical unmet need. Successful clinical trials and regulatory approval could position AZX1101 as a valuable tool in infection control, generating significant revenue streams within 5 years.
• Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of AzurRx's pipeline assets. Collaborations could provide access to additional funding, expertise, and distribution networks, enhancing the company's ability to bring its therapies to market. Securing such partnerships within the next 1-2 years would be a major catalyst for growth.
• Expansion of Pipeline: Expanding the company's pipeline through the acquisition or in-licensing of additional GI-focused therapies could diversify its product portfolio and reduce reliance on MS1819 and AZX1101. Identifying and securing promising new assets within the next 2-3 years would strengthen AzurRx's long-term growth prospects.
• Orphan Drug Designation: Pursuing orphan drug designation for MS1819 in specific patient populations could provide regulatory and commercial advantages, including market exclusivity and tax incentives. Obtaining orphan drug designation within the next year would enhance the attractiveness of MS1819 and support its development and commercialization efforts.

What Are AZRX's Competitive Advantages?

• Proprietary technology in developing non-systemic biologics.
• Patent protection for MS1819 and AZX1101.
• Clinical data supporting the safety and efficacy of their drug candidates.
• First-mover advantage in specific GI disorder treatments, if approved.

What Does AZRX Do?

AzurRx BioPharma, Inc., headquartered in Brooklyn, New York, is a biopharmaceutical company dedicated to the research and development of non-systemic biologics for the treatment of gastrointestinal (GI) disorders. Founded with the goal of addressing unmet medical needs in GI health, the company focuses on developing therapies that act locally within the GI tract to minimize systemic side effects. AzurRx's current product pipeline features two therapeutic proteins: MS1819 and AZX1101. MS1819 is an acid-resistant lipase intended for the treatment of exocrine pancreatic insufficiency (EPI), a condition often associated with chronic pancreatitis and cystic fibrosis. The company is developing MS1819 using recombinant DNA technology to produce a stable and effective enzyme replacement therapy. AZX1101 is a recombinant-lactamase combination under development for the prevention of hospital-acquired infections caused by resistant bacterial strains induced by parenteral administration of beta-lactam antibiotics, as well as the prevention of antibiotic-associated diarrhea (AAD). By focusing on non-systemic biologics, AzurRx aims to provide targeted therapies with improved safety profiles for patients suffering from debilitating GI conditions. The company currently employs 12 full-time employees and is navigating the complex regulatory landscape to advance its pipeline towards commercialization.

What Products and Services Does AZRX Offer?

• Develop non-systemic biologics for gastrointestinal disorders.
• Research and develop MS1819 for the treatment of exocrine pancreatic insufficiency (EPI).
• Develop AZX1101 for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
• Utilize recombinant DNA technology to produce therapeutic proteins.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Seek regulatory approvals from agencies like the FDA to commercialize their products.

How Does AZRX Make Money?

• Focus on research and development of novel therapies.
• Outsource manufacturing and clinical trial operations.
• Seek partnerships with larger pharmaceutical companies for commercialization.
• Generate revenue through product sales and licensing agreements, if approved.

What Industry Does AZRX Operate In?

The biotechnology industry is characterized by high R&D spending, lengthy regulatory approval processes, and intense competition. Companies like AzurRx BioPharma operate in a landscape where innovation and clinical success are paramount. The market for GI disorder treatments is substantial, driven by increasing prevalence of conditions like EPI and antibiotic-resistant infections. Competition includes both established pharmaceutical companies and other emerging biotech firms developing novel therapies. Success hinges on demonstrating clinical efficacy, securing regulatory approvals, and establishing commercial partnerships.

Who Are AZRX's Key Customers?

• Patients suffering from exocrine pancreatic insufficiency (EPI).
• Hospitals and healthcare providers seeking to prevent hospital-acquired infections.
• Patients at risk of antibiotic-associated diarrhea (AAD).
• Pharmaceutical companies interested in licensing or acquiring novel GI therapies.

AzurRx BioPharma, Inc. (AZRX) Valuation Context

Valued at $3.43M, AZRX is classified as a micro-cap stock.

AZRX Revenue & Earnings Trend

In Jun 2026, AZRX generated $86K in top-line revenue, marking a sequential increase of 124.8%. The company recorded a net loss of $221K, with diluted EPS of $-0.03. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, AZRX averaged $-0.86 in diluted EPS.

Company Profile

AzurRx BioPharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Brooklyn, US. The company is led by CEO James Sapirstein. AZRX has traded publicly since 2016.

Return on equity for AzurRx BioPharma, Inc. stands at -49.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.2%, showing how much profit it generates from its asset base. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -56.9%, the inverse of the P/E and a quick read on earnings relative to price.

AzurRx BioPharma, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.82 places it in the distress zone, a signal of elevated financial risk.

AzurRx BioPharma, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 82.5% below estimates on average.

The most recent 11 insider filings for AzurRx BioPharma, Inc. break down as 2 sales and 9 purchases. On net that is roughly 758K shares acquired (about $642K) — insiders putting money in tends to read as conviction.

AZRX Financials

AZRX Latest News

AzurRx BioPharma, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources